BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic, planning to create new ...

The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Further evidence from Pfizer that it is no longer dependent on income from COVID-19 products could be a catalyst for the ...

This eases the user's understanding of the market thoroughly, while also gaining knowledge about Anxiety Disorder Treatment market opportunities and the dominant players Pfizer Inc, Merck KGaA ...

Chronic Lower Back Pain (CLBP) market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...